Journal article
Effect of intensive structured care on individual blood pressure targets in primary care: Multicentre randomised controlled trial
S Stewart, MJ Carrington, CH Swemmer, C Anderson, NP Kurstjens, J Amerena, A Brown, LM Burrell, FJ De Looze, M Harris, J Hung, H Krum, M Nelson, M Schlaich, NP Stocks, GL Jennings
BMJ Online | Published : 2012
DOI: 10.1136/bmj.e7156
Abstract
Objective: To determine the effectiveness of intensive structured care to optimise blood pressure control based on individual absolute risk targets in primary care. Design: Pragmatic multicentre randomised controlled trial. Setting General practices throughout Australia, except Northern Territory, 2009-11. Participants: Of 2185 patients from 119 general practices who were eligible for drug treatment for hypertension according to national guidelines 416 (19.0%) achieved their individual blood pressure target during a 28 day run-in period of monotherapy. After exclusions, 1562 participants not at target blood pressure (systolic 150 (SD 17) mm Hg, diastolic 88 (SD 11) mm Hg) were randomised (1:..
View full abstractGrants
Funding Acknowledgements
[ "The VIPER-BP study was sponsored by Novartis Pharmaceuticals Australia. The sponsors participated in discussions on the design and conduct of the study and provided logistical support during the trial. The study statistician (Adrian Esterman, University of South Australia) independently generated analyses on behalf of the other members of the clinical safety and efficacy committee (Colin Johnston, MN, Richard Gerraty) who received remuneration from Novartis Pharmaceuticals Australia as study consultants. The study investigators and sponsor jointly assessed study data. All the investigators received remuneration from Baker IDI for the research component of clinical study activities.", "All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that all authors had a form of support (as described above) and specific relationships (as described above) with Novartis Pharmaceuticals Australia for the submitted work. SS, GLJ, and MJC are supported by the National Health and Medical Research Council of Australia. VIPER-BP study was supported by the Victoria government's operational infrastructure support program." ]